KR101173159B1 - 알칼로이드 제형 - Google Patents

알칼로이드 제형 Download PDF

Info

Publication number
KR101173159B1
KR101173159B1 KR1020067017766A KR20067017766A KR101173159B1 KR 101173159 B1 KR101173159 B1 KR 101173159B1 KR 1020067017766 A KR1020067017766 A KR 1020067017766A KR 20067017766 A KR20067017766 A KR 20067017766A KR 101173159 B1 KR101173159 B1 KR 101173159B1
Authority
KR
South Korea
Prior art keywords
formulation
alkaloid
electron transfer
phosphate
transfer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067017766A
Other languages
English (en)
Korean (ko)
Other versions
KR20060130195A (ko
Inventor
시몬 마이클 웨스트
에스라 오그루
로버트 지아넬로
Original Assignee
바이탈 헬스 사이언시즈 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004901107A external-priority patent/AU2004901107A0/en
Application filed by 바이탈 헬스 사이언시즈 피티와이 리미티드 filed Critical 바이탈 헬스 사이언시즈 피티와이 리미티드
Publication of KR20060130195A publication Critical patent/KR20060130195A/ko
Application granted granted Critical
Publication of KR101173159B1 publication Critical patent/KR101173159B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067017766A 2004-03-03 2005-03-03 알칼로이드 제형 Expired - Fee Related KR101173159B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2004901107A AU2004901107A0 (en) 2004-03-03 Alkaloid formulation
AU2004901107 2004-03-03
AU2004904367A AU2004904367A0 (en) 2004-08-03 Alkaloid formulations
AU2004904367 2004-08-03
PCT/AU2005/000307 WO2005084678A1 (en) 2004-03-03 2005-03-03 Alkaloid formulations

Publications (2)

Publication Number Publication Date
KR20060130195A KR20060130195A (ko) 2006-12-18
KR101173159B1 true KR101173159B1 (ko) 2012-08-16

Family

ID=34921028

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067017766A Expired - Fee Related KR101173159B1 (ko) 2004-03-03 2005-03-03 알칼로이드 제형

Country Status (14)

Country Link
US (2) US20060281716A1 (enExample)
EP (1) EP1720551B9 (enExample)
JP (1) JP4847437B2 (enExample)
KR (1) KR101173159B1 (enExample)
AT (1) ATE495730T1 (enExample)
AU (1) AU2005202477B2 (enExample)
BR (1) BRPI0508125A (enExample)
CA (1) CA2557354C (enExample)
DE (1) DE602005025979D1 (enExample)
DK (1) DK1720551T3 (enExample)
IL (1) IL177781A (enExample)
NZ (1) NZ549567A (enExample)
RU (1) RU2477136C2 (enExample)
WO (1) WO2005084678A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097472A1 (en) * 2000-11-14 2004-05-20 West Simon Michael Complexes of phosphate derivatives
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
MXPA04000654A (es) * 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
WO2003049774A1 (en) * 2001-12-13 2003-06-19 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
JP4690305B2 (ja) * 2003-01-17 2011-06-01 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗増殖性質を有する化合物
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
RU2477136C2 (ru) 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы
WO2006012692A1 (en) * 2004-08-03 2006-02-09 Vital Health Sciences Pty Ltd Carrier for enteral administration
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
JP2008531602A (ja) * 2005-03-03 2008-08-14 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗癌特性を有する化合物
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20090005348A1 (en) * 2005-12-23 2009-01-01 Vital Health Sciences Pty Ltd Compounds Having Cytokine Modulating Properties
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US10402738B2 (en) 2012-12-03 2019-09-03 National Ict Australia Limited Bayesian nonparametric method for infrastructure failure prediction
TWI685497B (zh) * 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TN2018000122A1 (en) 2015-11-16 2019-10-04 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2022082257A1 (en) 2020-10-19 2022-04-28 Avecho Biotechnology Limited Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
WO2022082256A1 (en) 2020-10-19 2022-04-28 Avecho Biotechnology Limited Oral cannabinoid formulation comprising tocopheryl phosphates and long chain triglycerides or long chain fatty acids
WO2022155656A1 (en) 2021-01-13 2022-07-21 Rodan & Fields, Llc Cosmetic compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
WO2004014432A1 (en) 2002-08-09 2004-02-19 Vital Health Sciences Pty Ltd Carrier

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407823A (en) * 1946-09-17 Antihemorrhagic esters and methods
US2667479A (en) * 1951-01-30 1954-01-26 Merck & Co Inc Benzimidazole phosphate
GB778142A (en) 1953-11-20 1957-07-03 Leo Ab High-molecular weight derivatives of hydroxyl group-containing steroids and a method of producing them
US2913477A (en) * 1957-03-22 1959-11-17 Merck & Co Inc Antihemorrhagic compounds and processes for preparing the same
US3127434A (en) * 1959-10-20 1964-03-31 Hoffmann La Roche Dihydrovitamin k monophosphate compounds and preparation thereof
US3212901A (en) * 1961-06-07 1965-10-19 Eastman Kodak Co Stabilized tocopherol concentrates and process for preparing the same
US3331896A (en) 1964-09-15 1967-07-18 Gen Aniline & Film Corp Method of preparing alkali soluble phosphate esters of hydroxylic organic compounds
US3607765A (en) 1968-11-29 1971-09-21 Colgate Polmolive Co Detergent softener compositions
DE2526938C2 (de) * 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
US4141938A (en) * 1976-10-07 1979-02-27 Hoechst Aktiengesellschaft Production of acid orthophosphoric acid ester mixtures
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
US4299906A (en) * 1979-06-01 1981-11-10 American Hoechst Corporation Light-sensitive color proofing film with surfactant in a light-sensitive coating
SU925961A1 (ru) 1980-08-15 1982-05-07 Московский ордена Трудового Красного Знамени технологический институт пищевой промышленности Способ получени фосфорилированных глицеридов высших жирных кислот
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IT1157269B (it) * 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
CH661438A5 (it) * 1984-04-09 1987-07-31 Seuref Ag Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
US4977282A (en) 1984-04-17 1990-12-11 Henkel Corporation Production of d-alpha-tocopherol from natural plant sources
US4603142A (en) 1984-06-01 1986-07-29 Wisconsin Alumni Research Foundation Cholesterol lowering method of use
EP0171009B1 (en) 1984-08-02 1991-05-22 HENKEL CORPORATION (a Delaware corp.) Purification of tocopherols by extraction
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
JPH0781138B2 (ja) 1986-12-02 1995-08-30 株式会社資生堂 抗酸化剤
DE3702766A1 (de) * 1987-01-30 1988-08-11 Henkel Kgaa Verfahren zur herstellung und isolierung von monoalkylphosphorsaeureestern
JP3070744B2 (ja) * 1987-04-10 2000-07-31 株式会社日立製作所 ベクトル処理装置
US4952495A (en) * 1987-06-08 1990-08-28 Eastman Kodak Company Hydrolyzable compounds which release electron transfer agents and analytical use of same
PH25859A (en) 1988-01-11 1991-12-02 Takeda Chemical Industries Ltd Composition for treatment of ischemic disorder
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DE3813624A1 (de) 1988-04-22 1989-11-02 Basf Ag Verfahren zur herstellung von d-(alpha)-tocopherol aus natuerlichen vorprodukten
CA2007643A1 (en) 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
US6028105A (en) 1989-04-06 2000-02-22 Nigra; Thomas P. Topical drug delivery composition and method
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
DE3927113C2 (de) * 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
JP2854631B2 (ja) 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
IT1236843B (it) 1989-11-22 1993-04-21 Simes Processo per la preparazione di 4-0-fosfati di dopamina o suoi derivati
JPH03206089A (ja) 1990-01-05 1991-09-09 Eisai Co Ltd 新規ビタミンｅ誘導体及びその製造方法
US5374645A (en) * 1990-01-22 1994-12-20 Ciba-Geigy Corporation Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol
FR2657526B1 (fr) 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5114957A (en) 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
US5643597A (en) * 1991-08-01 1997-07-01 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
FR2679904A1 (fr) * 1991-08-01 1993-02-05 Lvmh Rech Utilisation d'un phosphate de tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, ou pharmaceutiques et compositions ainsi obtenues.
EP0535283A1 (en) 1991-10-02 1993-04-07 Merrell Dow Pharmaceuticals Inc. Cardioprotective tocopherol analogs
US5474891A (en) * 1991-10-30 1995-12-12 Thomas Jefferson University Plasma-based platelet concentrate preparations with additive
DK0612521T3 (da) 1991-11-11 2000-01-17 Hisamitsu Pharmaceutical Co Keterolacholdigt varmt omslag
EP0543417A1 (en) * 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
US5282312A (en) * 1991-12-31 1994-02-01 Tessera, Inc. Multi-layer circuit construction methods with customization features
JP3202775B2 (ja) * 1992-01-29 2001-08-27 エスエス製薬株式会社 固形製剤
JP3207494B2 (ja) 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JPH05286848A (ja) 1992-04-10 1993-11-02 Senju Pharmaceut Co Ltd 浴用剤
GB9212450D0 (en) 1992-06-11 1992-07-22 Indena Spa New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them
US5741518A (en) * 1992-08-03 1998-04-21 L'oreal Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5348357A (en) 1992-12-24 1994-09-20 General Motors Corporation Vehicle closure latch having plastic coated ratchet
US6384043B1 (en) * 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
TW252918B (enExample) 1993-03-31 1995-08-01 Senju Pharma Co
GB9318271D0 (en) 1993-09-03 1993-10-20 Scotia Holdings Plc Tocopherols
CA2129509A1 (en) 1993-09-10 1995-03-11 Kazumi Ogata Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis
US5807542A (en) * 1993-11-27 1998-09-15 Knoll Aktiengesellschaft Chemical compositions for inhibiting nitrosation reaction in toiletries and cosmetics
JPH07196516A (ja) 1993-12-29 1995-08-01 Senju Pharmaceut Co Ltd 痔疾患治療剤
FR2714595B1 (fr) 1993-12-30 1996-02-02 Oreal Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement.
FR2715565B1 (fr) * 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
US5444957A (en) * 1994-02-01 1995-08-29 Roberts; Walter R. Multistory slab construction
EP0669132A1 (en) 1994-02-23 1995-08-30 van der Kraaij, Antonius Marinus Maria Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis
CA2145229A1 (en) 1994-03-29 1995-09-30 Tetsuya Toge Suppressory compositions against hepatic metastases of tumors
US5554781A (en) * 1994-03-30 1996-09-10 Reierson; Robert L. Monoalkyl phosphonic acid ester production process
JPH07277988A (ja) 1994-04-05 1995-10-24 Senju Pharmaceut Co Ltd 局所用掻痒除去、治療剤
TW287103B (enExample) 1994-04-22 1996-10-01 Senju Pharma Co
JP3362501B2 (ja) 1994-04-28 2003-01-07 千寿製薬株式会社 角膜障害治療剤
JP3396953B2 (ja) 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US5589504A (en) * 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
CA2152693A1 (en) 1994-08-05 1996-02-06 Kazumi Ogata Therapeutic composition for pancreatitis
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JPH0873338A (ja) * 1994-09-02 1996-03-19 Noevir Co Ltd 皮膚外用剤
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
DE4444238A1 (de) 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
FR2730928B1 (fr) * 1995-02-23 1997-04-04 Oreal Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique
DE69629989T2 (de) 1995-04-21 2004-07-22 Sekisui Kagaku Kogyo K.K. Präparate zur äusserlichen anwendung zur behandlung von dermatosen
US5607968A (en) * 1995-06-07 1997-03-04 Avon Products, Inc. Topical alkyl-2-O-L-ascorbyl-phosphates
CN1069320C (zh) * 1995-10-17 2001-08-08 昭和电工株式会社 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品
FR2741263B1 (fr) 1995-11-22 1997-12-26 Oreal Composition comprenant une dispersion aqueuse de vesicules lipidiques encapsulant un filtre uv a fonction acide et utilisations en application topique
NZ332426A (en) 1996-03-27 2000-09-29 Univ North Carolina Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5885595A (en) * 1996-05-13 1999-03-23 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic composition with a retinol fatty acid ester
CA2209690A1 (en) * 1996-07-31 1998-01-31 Sachiko Matsuura Therapeutic drug for acne vulgaris
JPH1067639A (ja) 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤
US6022867A (en) * 1996-11-27 2000-02-08 Showa Denko Kabushiki Kaisha Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals
JPH10155429A (ja) 1996-11-27 1998-06-16 Showa Denko Kk 動物に対するビタミンｅ供給方法および動物用トコフェロールリン酸エステル又はその塩類組成物
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
DE69840622D1 (de) 1997-01-29 2009-04-16 Kao Corp Kosmetikprodukt
CA2282513C (en) * 1997-03-13 2007-09-18 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
DE19824983C2 (de) * 1997-06-04 2001-06-28 Pacific Corp 2-(3-Aminopropylphosphorsäure)-L-ascorbat, Verfahren zu seiner Herstellung und dieses enthaltende kosmetische Zubereitung zur Aufhellung der Haut
US5928631A (en) * 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5776915A (en) 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
US6096326A (en) * 1997-08-15 2000-08-01 Scandinavian-American Import/Export Corporation Skin care compositions and use
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
WO1999039716A1 (en) 1998-02-03 1999-08-12 Senju Pharmaceutical Co., Ltd. Preventives and remedies for neuron digeneration-associated diseaseas
FR2777179A1 (fr) 1998-04-09 1999-10-15 Lvmh Rech Compositions cosmetiques ou dermatologiques comprenant un vehicule a base d'un liquide hydrophobe
US6461623B2 (en) * 1998-04-13 2002-10-08 Kao Corporation Cosmetic composition
JP4208209B2 (ja) 1998-06-22 2009-01-14 フジノン株式会社 コリメータレンズおよびこれを用いた光走査装置
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
JP2002519366A (ja) * 1998-07-07 2002-07-02 トランスダーマル・テクノロジーズ・インコーポレーテツド 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達
IL142082A (en) * 1998-09-23 2005-12-18 Res Dev Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses
US6703384B2 (en) * 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6770672B1 (en) * 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
AUPQ037499A0 (en) * 1999-05-14 1999-06-10 Swig Pty Ltd Improved process for phosphorylation and compounds produced by this method
AUPP829399A0 (en) * 1999-01-25 1999-02-18 Swig Pty Ltd Recovery for chroman derivatives
JP2000212082A (ja) 1999-01-26 2000-08-02 Showa Denko Kk 皮膚用剤
US6156354A (en) * 1999-01-29 2000-12-05 Brandeis University Hyper-absorption of vitamin E dispersed in milks
US6184247B1 (en) * 1999-05-21 2001-02-06 Amway Corporation Method of increasing cell renewal rate
WO2000072862A1 (en) * 1999-06-01 2000-12-07 Ocean Spray Cranberries, Inc. Cranberry seed oil extract and compositions containing components thereof
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6423742B1 (en) * 1999-09-02 2002-07-23 Drake Larson Compositions for reducing vascular plaque formation and methods of using same
CA2385989A1 (en) * 1999-09-27 2001-04-05 Andrew Nienstedt Compositions of tocol-soluble therapeutics
JP2001169731A (ja) 1999-12-17 2001-06-26 Showa Denko Kk 動物体の脂質代謝改善剤
RU2263672C2 (ru) * 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
US6635253B2 (en) * 2000-02-29 2003-10-21 Showa Denko Kabushiki Kaisha Composition for enhancing immunological effects
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
JP2001247585A (ja) 2000-03-03 2001-09-11 Nof Corp トコフェロール誘導体、その中間体、その製造方法及び用途
US6444220B2 (en) * 2000-03-16 2002-09-03 Teresa S. Wiley Method and compositions for changing the contour of skin
US6361800B1 (en) * 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6485950B1 (en) 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
KR100365070B1 (ko) 2000-08-29 2002-12-16 주식회사 태평양 토코페롤 유도체 및 그의 제조방법
JP4818500B2 (ja) * 2000-09-05 2011-11-16 株式会社ペンタプラストア トコトリエノール誘導体及びその製造方法
US20030206972A1 (en) * 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
WO2002040033A1 (en) * 2000-11-14 2002-05-23 Vital Health Sciences Pty Ltd Formulation containing phosphate derivatives of electron transfer agents
US20040097472A1 (en) * 2000-11-14 2004-05-20 West Simon Michael Complexes of phosphate derivatives
US20020132845A1 (en) 2000-12-15 2002-09-19 Miller Guy Michael Compositions and methods for the prevention and treatment of tissue ischemia
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
US20020131994A1 (en) * 2001-01-10 2002-09-19 Schur Henry B. Non-irritating formulation for the transdermal delivery of substances
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods
TW576859B (en) 2001-05-11 2004-02-21 Shipley Co Llc Antireflective coating compositions
KR100394770B1 (ko) 2001-06-05 2003-08-14 주식회사 태평양 토코페롤 유도체를 이용하여 나노유화입자를 안정화시키는방법 및 나노유화입자를 함유하는 피부 외용제 조성물
MXPA04000654A (es) * 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
AU2002951045A0 (en) * 2002-08-27 2002-09-12 Vital Health Sciences Pty Ltd Method of supplementing nascent endogenous storage forms
EP1429782A4 (en) * 2001-09-26 2005-02-02 Vital Health Sciences Pty Ltd MODULATION OF VITAMIN STORAGE
JP4370451B2 (ja) 2001-09-28 2009-11-25 大塚製薬株式会社 医薬組成物
JP2003128531A (ja) 2001-10-17 2003-05-08 Nonogawa Shoji Kk 皮膚外用剤
WO2003049774A1 (en) * 2001-12-13 2003-06-19 Vital Health Sciences Pty Ltd Transdermal transport of compounds
KR20040078543A (ko) 2002-01-31 2004-09-10 간사이 티.엘.오 가부시키가이샤 인간 암 예방용 조성물 및 인간 암 예방 방법
AU2003211131A1 (en) 2002-02-14 2003-09-04 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7074825B2 (en) 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
US20040067890A1 (en) * 2002-10-04 2004-04-08 Gupta Shyam K. Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions
US6645514B1 (en) 2002-12-19 2003-11-11 Access Business Group International, Llc Increasing skin cell renewal with water-soluble Vitamin E
JP4690305B2 (ja) * 2003-01-17 2011-06-01 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗増殖性質を有する化合物
US7033998B2 (en) * 2003-04-11 2006-04-25 All Natural Fmg, Inc. Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
AU2003901812A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphates of secondary alcohols
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
US7207669B2 (en) 2003-12-19 2007-04-24 Arizona Chemical Company Jet printing inks containing polymerized fatty acid-based polyamides
EP1718258B1 (en) 2004-02-23 2009-03-25 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
RU2477136C2 (ru) 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы
WO2006001473A1 (ja) 2004-06-29 2006-01-05 Japan Science And Technology Agency ヒアルロン酸を用いた小型肝細胞の選択的培養法および分離法
WO2006012692A1 (en) * 2004-08-03 2006-02-09 Vital Health Sciences Pty Ltd Carrier for enteral administration
US20060120979A1 (en) 2004-12-02 2006-06-08 Joel Rubin Skin care composition comprising hydroquinone and a substantially anhydrous base
US20090239827A1 (en) 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
JP2008531602A (ja) 2005-03-03 2008-08-14 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗癌特性を有する化合物
JP4270212B2 (ja) 2005-03-29 2009-05-27 セイコーエプソン株式会社 基板間隔調整装置、基板間隔調整方法、および液晶表示装置の製造方法
US20060228395A1 (en) 2005-04-11 2006-10-12 Robert Lamb Vitamin E phosphate/phosphatidylcholine liposomes to protect from or ameliorate cell damage
US9168216B2 (en) * 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
KR100764679B1 (ko) 2005-07-22 2007-10-09 익수제약 주식회사 파록세틴을 함유하는 경피투여용 패취제
US7446096B2 (en) 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US20090005348A1 (en) * 2005-12-23 2009-01-01 Vital Health Sciences Pty Ltd Compounds Having Cytokine Modulating Properties
WO2008034178A1 (en) 2006-09-21 2008-03-27 Salvatore Iemma Topical depilating composition
JP5201858B2 (ja) 2007-03-26 2013-06-05 花王株式会社 遊離脂肪酸が低減された油脂の製造方法
FR2921259B1 (fr) 2007-09-26 2015-02-13 Lvmh Rech Utilisation cosmetique du phosphate de tocopherol comme agent anti-vieillissement de la peau
EP2113242A1 (en) 2008-05-02 2009-11-04 Pangaea Laboratories Limited Antioxidant for use in cosmetic, medicated and pharmaceutical preparations
US20090297591A1 (en) 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
JP5132700B2 (ja) 2010-02-22 2013-01-30 三菱電機株式会社 手乾燥装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
WO2004014432A1 (en) 2002-08-09 2004-02-19 Vital Health Sciences Pty Ltd Carrier

Also Published As

Publication number Publication date
RU2477136C2 (ru) 2013-03-10
WO2005084678A1 (en) 2005-09-15
IL177781A (en) 2015-03-31
US20100209459A1 (en) 2010-08-19
DK1720551T3 (da) 2011-05-16
KR20060130195A (ko) 2006-12-18
HK1098684A1 (en) 2007-07-27
EP1720551B1 (en) 2011-01-19
BRPI0508125A (pt) 2007-07-17
US20060281716A1 (en) 2006-12-14
CA2557354C (en) 2013-05-07
RU2006131997A (ru) 2008-04-10
AU2005202477A1 (en) 2005-09-22
CA2557354A1 (en) 2005-09-15
EP1720551B9 (en) 2011-09-21
ATE495730T1 (de) 2011-02-15
JP4847437B2 (ja) 2011-12-28
US8529947B2 (en) 2013-09-10
NZ549567A (en) 2009-10-30
IL177781A0 (en) 2006-12-31
EP1720551A4 (en) 2007-04-04
JP2007526256A (ja) 2007-09-13
DE602005025979D1 (de) 2011-03-03
AU2005202477B2 (en) 2005-12-15
EP1720551A1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
US8529947B2 (en) Alkaloid formulations
ES2643643T3 (es) Composición portadora para suministro de un compuesto biológicamente activo
EP2910242B1 (en) Durable analgetic sebacoyl dinalbuphine ester-plga controlled release formulation
RU2377019C2 (ru) Транспортирующий наполнитель для энтерального применения
JP2001520656A (ja) 抗腫瘍剤としてのホルボールエステル類
CN108366975A (zh) 使用脱氧胆酸和其盐对堆积的脂肪的治疗
EP1559426B1 (en) Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one
ZA200105275B (en) New use of melagatran.
EP4208160A1 (en) Ionic liquid formulations for treating diabetes
JPH0640914A (ja) フィソスチグミンの新誘導体、それらの用途及びそれらを含む製薬組成物
CN118924766A (zh) 五环三萜结构修饰化合物在制备白癜风药物中的应用及新制剂
CN1946401B (zh) 生物碱制剂
HK1098684B (en) Alkaloid formulations
NZ522450A (en) Methods for prevention of ulcers
MXPA06009912A (en) Alkaloid formulations
WO1995034262A1 (en) Transdermal treatment of malaria
KR101625926B1 (ko) 포스포디에스터라제 타입-5 억제제의 경피 전달을 향상시키는 방법 및 포스포디에스터라제 타입-5 억제제의 경피 전달을 향상시키는 개선된 약학적 조성물
RU2660353C2 (ru) Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
WO1998022102A1 (en) Pharmaceutical compositions containing 3-iodo-1,2-propanediol having mucolytic activity
JP4477504B2 (ja) 鎮痒剤
JP2011513278A (ja) カンナビノイド受容体結合化合物およびオピオイドを含む組合せ

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150730

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160807

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160807

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000